Evidence mapPaperPMID 41858496Full record

ReviewJournal of pharmaceutical policy and practice2026

Regulatory and HTA framework for herbal medicines in Indonesia.

Mohamad Kashuri, Taruna Ikrar, Rani Sauriasari, Vishnu Juwono, Arry Yanuar

Abstract readReview
In one paragraph

Review in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohamad KashuriFaculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.ORCID https://orcid.org/0009-0007-3422-1863
Taruna IkrarThe Indonesian Food and Drug Authority, Jakarta, Indonesia.ORCID https://orcid.org/0000-0002-8081-8528
Rani SauriasariFaculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.ORCID https://orcid.org/0000-0001-7861-4369
Vishnu JuwonoFaculty of Administrative Science, Universitas Indonesia, Depok, Indonesia.ORCID https://orcid.org/0000-0002-0928-1860
Arry YanuarFaculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.ORCID https://orcid.org/0000-0001-8895-9010

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Herbal medicines are widely used in Indonesia and other LMICs, yet their integration into national health systems relies on coherent regulatory oversight, reliable evidence generation, functional pharmacovigilance (PV), and alignment with health technology assessment (HTA) and financing processes. Existing evidence varies in rigour and maturity, creating uncertainty for regulators and policymakers. A consolidated understanding of how available evidence informs regulatory, HTA, PV, and financing decisions is needed to guide a more predictable, evidence-informed governance framework for herbal medicines in Indonesia. Methods: An integrative review was conducted using Scopus, PubMed, Google Scholar, WHO IRIS, the ASEAN TMHS repository, and national regulatory portals for literature published between 2015 and 2025. Thirty-seven studies met eligibility and WHO-based methodological quality criteria. Data were extracted using a structured matrix, synthesised thematically, and deductively mapped to five analytic domains: evidence generation, regulatory pathways, HTA processes, pharmacovigilance systems, and financing-governance alignment. Results: Three system-level themes emerged. First, substantial misalignment exists between available evidence and regulatory requirements, driven by heterogeneous clinical methods, limited comparator data, and variable standardisation. Second, HTA remains weakly integrated into decision-making due to gaps in clinical effectiveness, limited economic evidence, and challenges in assessing multi-component interventions. Third, PV and governance systems show fragmentation, weak inter-agency coordination, and inadequate safety signal detection. These interdependent weaknesses reduce regulatory predictability, constrain HTA feasibility, and limit informed financing decisions. Conclusion: This review provides the first integrated synthesis of evidence generation, regulatory pathways, HTA processes, PV systems, and financing-governance alignment for herbal medicines in Indonesia. Findings highlight the need to strengthen evidence standards, adapt HTA methodologies, reinforce PV and laboratory capacity, and improve regulatory-financing linkages. Implementing the proposed framework can enhance policy coherence, regulatory transparency, and safety oversight, supporting more credible and evidence-informed integration of herbal medicines into Indonesia's health system.

Indexed as

Evidence generationhealth technology assessmentherbal medicinespharmacovigilanceregulatory framework

Identifiers

PMID41858496
PMCPMC12997360

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.